Acta Med. 2014, 57: 157-161

https://doi.org/10.14712/18059694.2015.81

ASPIRIN RESISTANCE IN NEUROVASCULAR DISEASES

Martin Vališa, Dagmar Krajíčkováa, Jaroslav Malýb, Radovan Malýb, Ilona Fátorováb, Oldřich Vyšataa,c, Roman Herziga

aUniversity Hospital Hradec Králové and Charles University in Prague, Faculty of Medicine in Hradec Králové, Comprehensive Department of Neurology, Stroke Center, Czech Republic
bUniversity Hospital Hradec Králové and Charles University in Prague, Faculty of Medicine in Hradec Králové, Department of Internal Medicine, Czech Republic
cDepartment of Computing and Control Engineering, Institute of Chemical Technology, Prague, Czech Republic

Received January 17, 2014
Accepted January 28, 2015

References

1. Michelson AD, Cattaneo M, Eikelboom JW, et al.; Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis; Working Group on Aspirin Resistance. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005; 3: 1309–11. <https://doi.org/10.1111/j.1538-7836.2005.01351.x>
2. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849–60.
3. Berger JS, Krantz MJ, Kittelson JM, et al. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 2009; 301: 1909–19. <https://doi.org/10.1001/jama.2009.623>
4. Antithrombotic Trialistsʼ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in high-risk patients. BMJ 2002; 324: 71–86.
5. Cattaneo M. Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection. J Thromb Haemost 2007; 5(Suppl 1): 230–7. <https://doi.org/10.1111/j.1538-7836.2007.02498.x>
6. Cheng X, Chen WH, Simon DI. Aspirin resistance or variable response or both? Am J Cardiol 2006; 98: 11–7. <https://doi.org/10.1016/j.amjcard.2006.09.009>
7. Patrono C, Baigent C, Hirsh J, Roth G; American College of Chest Physicians. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6 Suppl): 199S–233S.
8. Mason PJ, Freedman JE, Jacobs AK. Aspirin resistance: current concepts. Rev Cardiovasc Med 2004; 3: 156–63.
9. McKee SA, Sane DC, Deliargyris EN. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms and clinical significance. Thromb Haemost 2002; 88: 711–5. <https://doi.org/10.1055/s-0037-1613290>
10. Buchanan MR, Bister SJ. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol 1995; 11: 221–7.
11. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650–5. <https://doi.org/10.1161/01.CIR.0000013777.21160.07>
12. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230–4. <https://doi.org/10.1016/S0002-9149(01)01631-9>
13. Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994; 25: 2331–6. <https://doi.org/10.1161/01.STR.25.12.2331>
14. Macchi L, Christiaens L, Brabant S, et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002; 107: 45–9. <https://doi.org/10.1016/S0049-3848(02)00210-4>
15. Zimmermann N, Hohlfeld T. Clinical implications of aspirin resistance. Thromb Haemost 2008; 100: 379–90. <https://doi.org/10.1160/TH08-01-0056>
16. Hankey GJ, Eikelboom JW. Aspirin resistence. Lancet 2006; 367: 606–7. <https://doi.org/10.1016/S0140-6736(06)68040-9>
17. Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006; 27: 647–54. <https://doi.org/10.1093/eurheartj/ehi684>
18. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. JACC 2003; 41: 961–5. <https://doi.org/10.1016/S0735-1097(02)03014-0>
19. Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008; 336: 195–8. <https://doi.org/10.1136/bmj.39430.529549.BE> <PubMed>
20. Sztriha LK, Sas K, Vecsei L. Aspirin resistance in stroke: 2004. J Neurol Sci 2005; 229/230: 163–9. <https://doi.org/10.1016/j.jns.2004.11.023>
21. Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance J Am Coll Cardiol 2006; 47: 27–33. <https://doi.org/10.1016/j.jacc.2005.08.058>
22. Fifi JT, Brockington C, Narang J, et al. Clopidogrel resistance is associated with thromboembolic complications in patients undergoing neurovascular stenting. Am J Neuroradiol 2013; 34: 716–20. <https://doi.org/10.3174/ajnr.A3405> <PubMed>
23. Mijajlovic MD, Shulga O, Bloch S, Covickovic-Sternic N, Aleksic V, Bornstein NM. Clinical consequences of aspirin and clopidogrel resistance: an overview. Acta Neurol Scand 2013; 128: 213–9. <https://doi.org/10.1111/ane.12111>
24. Addad F, Hassine M, Ben Farhat M, et al. Intra-individual variability of the platelet anti-aggregation effect of aspirin in coronary patients. Arch Mal Coeur Vaiss 2005; 98: 979–83.
25. Oqueli E, Hiscock M, Dick R. Clopidogrel resistance. Heart Lung Circ 2007; 16 Suppl 3: S17–28. <https://doi.org/10.1016/j.hlc.2007.03.012>
26. Greer DM. Aspirin and antiplatelet agent resistance: implications for prevention of secondary stroke. CNS Drugs 2010; 24: 1027–40. <https://doi.org/10.2165/11539160-0000000000-00000>
27. Jeon SB, Song HS, Kim BJ, et al. Biochemical aspirin resistance and recurrent lesions in patients with acute ischemic stroke. Eur Neurol 2010; 64: 51–7. <https://doi.org/10.1159/000315147>
28. Cattaneo M. High on-treatment platelet reactivity – definition and measurement. Thromb Haemost 2013; 109: 792–8. <https://doi.org/10.1160/TH12-10-0758>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive